Targeted Oncology features Actinium for “86% Remission Rate Observed in Chemotherapy and ARC Combination in Relapsed/Refractory AML” Mar 10, 2020
Hematology Advisor writes about Actinium’s TCTM 2020 Poster Presentation in “Mobile Shields May Reduce Iodine-131 Exposure From Iodine Apamistamab Treatment for AML” Mar 6, 2020
Actinium’s TCTM 2020 Oral Presentation in ASTCT’s “Biology of Blood and Marrow Transplantation” Mar 1, 2020
Actinium’s TCTM 2020 Poster Presentation in ASTCT’s “Biology of Blood and Marrow Transplantation” Mar 1, 2020
Phase 3 of Actinium’s SIERRA Trial in ASTCT’s “Biology of Blood and Marrow Transplantation” Mar 1, 2020
Actinium in Healio’s HemOnc Today article “Targeted Conditioning improves transplant rate for relapsed, refractory AML” Feb 28, 2020
MedPage Today covers Actinium TCTM 2020 Oral Presentation Findings: “Bringing Transplant to More Patients with AML” Feb 25, 2020
OncLive Covers Actinium’s Phase 3 SIERRA Trial from TCTM 2020: “Conditioning Therapy With Iomab-B Leads to High Transplant Rate in Active AML” Feb 21, 2020
“SIERRA Trial: Background on the Iomab-B Combination in Relapsed/Refractory AML” in Targeted Oncology Feb 18, 2020
Actinium ASH presentation highlighted in Feb 2020 issue of Value-Based Cancer Care: “Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome” Feb 1, 2020